WO2020117002A1 - Méthode pour établir le pronostic d'un carcinome épidermoïde oesophagien - Google Patents

Méthode pour établir le pronostic d'un carcinome épidermoïde oesophagien Download PDF

Info

Publication number
WO2020117002A1
WO2020117002A1 PCT/KR2019/017213 KR2019017213W WO2020117002A1 WO 2020117002 A1 WO2020117002 A1 WO 2020117002A1 KR 2019017213 W KR2019017213 W KR 2019017213W WO 2020117002 A1 WO2020117002 A1 WO 2020117002A1
Authority
WO
WIPO (PCT)
Prior art keywords
genes
expression
gene
protein
cell carcinoma
Prior art date
Application number
PCT/KR2019/017213
Other languages
English (en)
Korean (ko)
Inventor
이용선
김인후
Original Assignee
국립암센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 국립암센터 filed Critical 국립암센터
Publication of WO2020117002A1 publication Critical patent/WO2020117002A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • the present invention relates to a method for predicting the prognosis of esophageal squamous cell carcinoma.
  • ncRNAs non-coding RNAs
  • PLR Protein Kinase R
  • Dicer Dicer
  • Another feature of nc886 is that it is transcribed by RNA polymerase III, which is very different from most regulatory ncRNA transcribed by RNA polymerase II. nc886 began to receive attention after the dysregulation was found in various malignant tumors.
  • nc886 is expressed in most normal tissues, but its expression is epigenetically silent in many malignancies such as gastric cancer and acute myeloid leukemia.
  • a prominent phenotypic result that appears when expression of nc886 changes is cell proliferation. Therefore, it was assumed that nc886 was a tumor suppressor, and the silence of nc886 was expected to promote cell proliferation. Nevertheless, when nc886 was treated with anti-sense oligonucleotides in some nc886 + cell lines derived from the esophagus, stomach, etc., the expression of nc886 was rapidly reduced and cell proliferation was reduced.
  • nc886 is a molecular function that inhibits PKR.
  • PKR is a procytic protein (a protein that induces apoptosis) that is typically activated by viral infection. The rapid decrease in nc886 is sufficient to activate PKR without viral infection. When PKR is activated, it phosphorylates elF2 ⁇ , thereby stopping the translation of the entire protein and inducing cell death.
  • nc886 silencing and PKR activation (and thereby apoptosis) in vivo is thought to act as a boundary for removing pre-cancerous cells, such as PKR activation removing virus-infected cells.
  • nc886 silencing confers growth benefits on cells at certain stages of cancer development.
  • nc886 In a situation where nc886 is silenced, it is thought that the growth promoting effect in addition to the PKR-eIF2 ⁇ cell death pathway also occurs, and these two are separate pathways.
  • PKR-eIF2 ⁇ cell death pathway When experimentally inducing the silence of nc886, cell death according to the PKR pathway occurs first, so it is not easy to observe the cell growth promoting phenotype due to the silence of nc886.
  • AKT cyclin-dependent kinase
  • E2F activity is inhibited by AKT, and some CDK inhibitors (such as CDKN2A and CDKN2C) have been reported to be transcriptionally activated by E2F. Therefore, AKT inhibits E2F, thereby weakening the transcription of the CDK inhibitor gene. In addition, crosstalk between AKT and SKP2 has been reported.
  • SKP2 a regulatory component of the SKP1:CUL1:F-box protein complex (SCF), is overexpressed in malignant tumors and instructs to break down CDK inhibitory proteins through SCF E3 ubiquitinase. do.
  • Esophageal cancer is a generic term for cancer that occurs in the esophagus, and is not one of the most common cancers in Korea. Therefore, measuring a patient's prognosis prediction is one of the most important studies.
  • Korean Patent No. 10-1657033 discloses a method of predicting the survival rate and prognosis of esophageal cancer patients by measuring the protein expression level of V-ATPase subunit V1E1, and Korean Patent Publication No. 10-2008-0007659
  • the disclosure discloses compositions and methods for the diagnosis of esophageal cancer and esophageal cancer metastasis by detecting specific genes.
  • Esophageal cancer is largely divided into esophageal squamous cell carcinoma and esophageal adenocarcinoma.
  • esophageal squamous cell carcinoma is a cancer originating from flat cells, which are the main cells that make up the esophagus.
  • the present inventors conducted a study on the importance of suppressing nc886 in esophageal squamous cell carcinoma, and propose a method to more accurately predict the prognosis of esophageal squamous cell carcinoma patients.
  • the present inventors studied the importance of inhibiting nc886 in esophageal squamous cell carcinoma, and confirmed that low expression of nc886 in esophageal squamous cell carcinoma promotes the proliferation of cancer cells. Furthermore, nc886 expression delays the cell cycle, and the cell cycle It was confirmed that the gene was regulated and the target genes of AKT were changed. It is confirmed that the prognosis of esophageal squamous cell carcinoma patients can be predicted by measuring the expression of nc886 in patients with esophageal squamous cell carcinoma, the increase or decrease in the target gene expression of AKT, and the increase or decrease in the expression of genes related to the existing TNM stage and cell cycle. Thus completed the present invention.
  • the present invention comprises: a) measuring the expression level of nc886 from a biological sample isolated from a patient with esophageal squamous cell carcinoma; b) measuring the expression level of any one or more of genes whose expression changes according to an increase in nc886 among AKT target genes and genes whose expression changes according to an increase in nc886 among genes related to cell cycle; To provide a method for providing information for predicting the prognosis of patients with esophageal squamous cell carcinoma.
  • nc886 When the expression level of nc886 is low; b-1) the target gene of AKT has a "expression level of a gene or protein reduced by increasing expression of nc886" higher than a normal control sample; Or “The level of a gene or protein increased by increased expression of nc886” is lower than a normal control sample; And/or b-2) among the genes associated with the cell cycle, "the expression level of a gene or protein reduced by an increase in expression of nc886" is higher than a normal control sample; Alternatively, if the expression level of the gene or protein thereof increased by increasing the expression of nc886 among the genes associated with the cell cycle is lower than the control sample, the prognosis of the esophageal squamous cell carcinoma patient may be determined to be poor.
  • collecting the information classified according to TNM for the esophageal squamous cell carcinoma may further include.
  • the classification score is calculated from 0 to 4, and if the score is 0, it can be judged to be very good if it is 0, good if it is 1, good if it is 2, bad when it is 3, and very bad if it is 4. .
  • the present invention in one preferred embodiment, can provide a method for providing information necessary for predicting the prognosis of esophageal squamous cell carcinoma comprising the following steps.
  • nc886 If the expression level of nc886 is higher than the normal control sample, 0 point is given; if it is lower than the normal sample control, 1 point is given,
  • the expression level of a gene or its protein that decreases due to an increase in expression of nc886 is higher than a normal control sample, or a gene or its protein level that increases by an increase in expression of nc886” 1 point is given if it is lower than the normal control sample;
  • the expression level of a gene or its protein that decreases due to increased expression of nc886” is lower than the normal control sample, or a gene or its protein level that increases by increased expression of nc886” is higher than a normal control sample. If it's high, give it 0,
  • the expression level of a gene or its protein that decreases by increasing the expression of nc886 among genes related to the cell cycle is higher than a normal control sample, or increased by an increase in expression of nc886 among genes related to the cell cycle. If the level of expression of a gene or a protein thereof” is lower than a normal control sample, 1 point is given; The expression level of a gene or its protein that decreases due to an increase in expression of nc886 among genes related to the cell cycle is lower than a normal control sample, or a gene or its increase that increases by an increase in expression of nc886 among genes related to the cell cycle. If the level of protein expression” is higher than the normal control sample, 0 point is given,
  • TNM step is 1 or 2, giving 0 points, and if it is 3 or 4, giving 1 point;
  • genes that decrease by increasing expression of nc886 are ACLY, BTK, CD14, CDC42, CDKN1A, CDKN1B, DPYSL2, DPYSL3, EIF4E, FOS, FOXO1, FOXO3, FOXO4, GJA1, GRB10, Any gene selected from the group consisting of GRB2, HSPB1, JUN, MAP3K5, MAPT, MYC, NFKBIA, PABPC1, PAK1, PALLD, PIK3R1, PPP2R1B, PRKAA1, PRKCA, PRKCZ, SHC1, SREBF1, SRF and YWHAH, Genes increased by increased expression of nc886 include ATG4B, BCL2L11, CSNK2A1, CTPS, EIF2AK2, FKBP1A, GADD45A, HRAS, MAPK1, MAPKAP1, MTCP1, PCK2, PPP2CB, PPP2R2A,
  • genes increased by increased expression of nc886 are CDKN2A, RBL1, PPP2R1B, CDKN1A or CDKN2C
  • genes decreased by increased expression of nc886 are SKP2, CDKN1B, PPP2CB, UBA52, CDK4, It may be RPS27A, PPP2CA, PPP2R2A or CUL1.
  • the biological sample isolated from the esophageal squamous cell carcinoma patient may be a formalin-fixed paraffin-embedded (FFPE) sample, fresh tissue or frozen tissue of tissue containing cancer cells of the patient, , but is not limited to this.
  • FFPE formalin-fixed paraffin-embedded
  • the level of the gene is polymerase reaction (PCR), reverse transcriptase reaction (RT-PCR), competitive reverse transcriptase reaction (Competitive RT-PCR), real-time reverse transcriptase reaction (Realtime RT) -PCR), RNase protection assay (RPA; RNase protection assay), Northern blotting, next-generation sequencing (NGS) and DNA microarray analysis Can be measured by PCR, reverse transcriptase reaction (RT-PCR), competitive reverse transcriptase reaction (Competitive RT-PCR), real-time reverse transcriptase reaction (Realtime RT) -PCR), RNase protection assay (RPA; RNase protection assay), Northern blotting, next-generation sequencing (NGS) and DNA microarray analysis Can be measured by
  • the expression level of the protein is Western blot, ELISA (enzyme linked immunosorbent asay), immunostaining, radioimmunoassay (RIA), radioimmunodiffusion, oruktero
  • ELISA enzyme linked immunosorbent asay
  • RIA radioimmunoassay
  • the present invention also provides nc886; And ACLY, BTK, CD14, CDC42, CDKN1A, CDKN1B, DPYSL2, DPYSL3, EIF4E, FOS, FOXO1, FOXO3, FOXO4, GJA1, GRB10, GRB2, HSPB1, JUN, MAP3K5, MAPT, MYC, NFKBA, PANKBD , PIK3R1, PPP2R1B, PRKAA1, PRKCA, PRKCZ, SHC1, SREBF1, SRF, YWHAH, ATG4B, BCL2L11, CSNK2A1, CTPS, EIF2AK2, FKBP1A, GADD45A, HRAS, MAPK1, MAPK2, PAPCPP , THEM4, YWHAE, YWHAG, CDKN2A, CDKN2C, SKP2, UBA52, CDK4, RPS27A, PPP2CA, RBL1 or CUL1 gene, or a
  • the present invention also provides nc886; And ACLY, BTK, CD14, CDC42, CDKN1A, CDKN1B, DPYSL2, DPYSL3, EIF4E, FOS, FOXO1, FOXO3, FOXO4, GJA1, GRB10, GRB2, HSPB1, JUN, MAP3K5, MAPT, MYC, NFKBA, PANKBD , PIK3R1, PPP2R1B, PRKAA1, PRKCA, PRKCZ, SHC1, SREBF1, SRF, YWHAH, ATG4B, BCL2L11, CSNK2A1, CTPS, EIF2AK2, FKBP1A, GADD45A, HRAS, MAPK1, MAPK2, PAPCPP , THEM4, YWHAE, YWHAG, CDKN2A, CDKN2C, SKP2, UBA52, CDK4, RPS27A, PPP2CA, RBL1 or CUL1 gene, or a
  • the present invention can also provide a biomarker composition for predicting resistance or sensitivity to the anticancer agent palbociclib in esophageal squamous cell carcinoma comprising an agent measuring the mRNA or protein level of the nc886, AKT, CDK4, CDKN2A and CKN2C genes. .
  • the present invention can also provide a kit for predicting the resistance or sensitivity to the anticancer agent palbociclib in esophageal squamous cell carcinoma comprising the above-described composition.
  • the present invention can also provide a method for providing information for predicting resistance or sensitivity to the anticancer agent palbociclib in esophageal squamous cell carcinoma comprising the following steps.
  • nc886, CDKN2A and CKN2C gene mRNA or its protein level is lower than the control
  • AKT and CDK4 gene mRNA or its protein level is higher than the control group
  • esophageal squamous cell carcinoma susceptibility to anticancer agent palbociclib If it is judged that there is, and the mRNA level of the nc886, CDKN2A and CKN2C genes or its protein level is higher than the control group, and the mRNA level of the AKT and CDK4 genes or the protein level thereof is lower than the control group, the anticancer agent in the esophageal squamous cell carcinoma is used as an anticancer agent Determining that there is resistance to.
  • the biological sample of step a) is a formalin-fixed paraffin-embedded (FFPE) sample of tissue containing cancer cells of a patient with esophageal squamous cell carcinoma, fresh tissue, and It may be one or more selected from the group consisting of frozen tissue.
  • FFPE formalin-fixed paraffin-embedded
  • the mRNA levels of step (a) are polymerase reaction (PCR), reverse transcriptase reaction (RT-PCR), competitive reverse transcriptase reaction (Competitive RT-PCR), real-time reverse transcriptase reaction (Realtime RT-PCR), RNase protection assay (RPA), Northern blotting, next-generation sequencing (NGS), and DNA microarray analysis.
  • PCR polymerase reaction
  • RT-PCR reverse transcriptase reaction
  • Competitive RT-PCR competitive reverse transcriptase reaction
  • Realtime RT-PCR real-time reverse transcriptase reaction
  • RNase protection assay RNase protection assay
  • NGS next-generation sequencing
  • the protein level of step (a) is western blotting, ELISA (enzyme linked immunosorbent assay), radioimmunoassay, radioimmunodiffusion, ouchterlony immunodiffusion, rocket (Rocket) from the group consisting of immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complete fixation assay, flow cytometry (FACS) and protein chip assay It may be measured by one or more methods selected.
  • the present invention measures the expression of genes related to AKT target genes and cell cycles regulated by nc886 and nc886 in patients with esophageal squamous cell carcinoma, and comprehensively scores them by summing the existing TNM stages, thereby accurately predicting the prognosis of patients with esophageal squamous cell carcinoma. It has a predictable effect.
  • by measuring the mRNA or protein level of the nc886, AKT, CDK4, CDKN2A and CKN2C genes there is an effect that can predict the resistance or sensitivity to the anticancer agent palbosilib in esophageal squamous cell carcinoma.
  • A is a schematic diagram of the plasmid used in the present invention
  • B is a RT-PCR result confirming the expression of nc886 in a cell line stably inserted with the plasmid
  • C is a result showing the proliferation of the cell number of the cells used in the present invention
  • D is a schematic diagram showing a cell mixing experiment
  • EF is the result of measuring FACS GFP negative and positive cell number.
  • a and B are the results of confirming the cell cycle after staining DNA with propidium iodide (PI).
  • FIG. 3 shows the results of analyzing the nc886-EXP and nc886-KD array data in an integrated MSigDB (Molecular Signature Database).
  • A shows the Z-scores for the 674 Reactome gene set nc886-EXP (x-axis) and nc886-KD. Schematically plotted between (y-axis) to show the correlation, B is the result of showing the Z-score for 615 TFT (TF target gene set) as a scatterplot as described in panel A, and CD is the Reactome gene A bar graph showing the significantly enhanced TFT Z-scores (>3, based on nc886-EXP) in the set and TFT gene sets.
  • FIG. 4 shows the results showing that nc886 regulates the expression of cell cycle genes
  • A is the Venn diagram results of cell cycle genes (40 genes) and genes altered by nc886, and B is 108 ESCC patients Volcano map of 19 nc886/G1-related genes showing statistical correlation with nc886 expression in the cohort
  • C is the correlation between nc886 expression and a representative cell cycle gene in 108 ESCC patient cohorts
  • D Is the qRT-PCR result of the gene.
  • A is a heat map result showing RPPA data from nc886-KD of ES1, an ESCC cell line
  • B is a Western blot result measuring the expression levels of phosphorylated AKT and total AKT.
  • C is a GSEA result demonstrating whether the AKT gene set a priori defined in nc886 KD shows statistical agreement in ESCC patients according to nc886 expression.
  • A is a result showing that the combination of nc886, AKT signature score, cell cycle signature score, and TNM stage is the strongest predictor of relapse and survival
  • b TNM stage stage I and II (0)/stage III and IV (1)
  • degree of nc886 expression high (0)/low (1) as median
  • AKT signature score low (0)/ as median
  • cell cycle scores low (0)/high (1) by median values
  • C is a summary of this study.
  • FIG. 7 shows the prognostic and predictive values of nc886,
  • A shows that a number of genes including CDK4 are upregulated in Cluster 2 as a result of the undirected cluster of AKT and cell cycle genes in the ESCC cohort
  • B is the result of confirming the expression of nc886 in Cluster 1 and Cluster 2
  • C is the result of confirming the expression of nc886 in the esophageal cell line using qRT-PCR
  • D is the weak sensitivity of the 30 EC cell line to Palbosiclip
  • F is the result of analyzing apoptosis of the esophageal cell line showing the inverse correlation of the expression level of nc886 to the sensitivity to Palbociclib.
  • Esophageal cancer is a generic term for cancer that occurs in the esophagus. Esophageal cancer is not one of the most common cancers in Korea, but prognosis is one of the most dangerous cancers. Therefore, measuring a patient's prognosis prediction is one of the most important studies. In the present invention, it was confirmed that low expression of nc886 in esophageal squamous cell carcinoma promotes the proliferation of cancer cells. It was confirmed that the expression of nc886 delayed the cell cycle, regulated the cell cycle gene, and changed the target genes of AKT.
  • the prognosis of esophageal squamous cell carcinoma patients can be predicted by measuring the expression of nc886 in patients with esophageal squamous cell carcinoma, increasing or decreasing the target gene expression of AKT, and increasing or decreasing the expression of genes related to the existing TNM stage and/or cell cycle.
  • the present invention was completed by confirming that.
  • the present invention comprises the steps of measuring the expression level of nc886 from a biological sample isolated from a patient with esophageal squamous cell carcinoma; b) measuring the expression level of any one or more of genes whose expression changes according to an increase in nc886 among AKT target genes and genes whose expression changes according to an increase in nc886 among genes related to cell cycle; It can provide a method for providing information for predicting the prognosis of patients with esophageal squamous cell carcinoma.
  • the expression of the measured or collected nc886, the increase or decrease of the target gene expression of AKT, the increase or decrease of the expression of the gene associated with the existing TNM stage and/or cell cycle is scored, and can be determined by summing it The weight of each expression level and stage can be used to more accurately predict the prognosis of patients with esophageal squamous cell carcinoma.
  • the expression level of a gene or its protein that decreases by increasing expression of nc886 among the target genes of AKT is higher than a normal control sample;
  • the level of a gene or protein increased by an increase in expression of nc886 is lower than a normal control sample;
  • the expression level of a gene or its protein that decreases by increasing the expression of nc886 among genes related to the cell cycle is higher than a normal control sample; Or if the expression level of the gene or its protein increased by increasing the expression of nc886 among genes related to the cell cycle is lower than the control sample as expected; it can be determined that the prognosis of patients with esophageal squamous cell carcinoma is poor.
  • collecting the information classified according to TNM for the esophageal squamous cell carcinoma may further include.
  • the stage of the TNM is 3 or 4; it can be determined that the prognosis of the esophageal squamous cell carcinoma patient is poor. Poor prognosis may mean that the disease-specific survival year, recurrence free survival, or overall survival is lower than the good prognosis group.
  • the TNM may refer to the standard of the 7th revision of AJCC as a criterion for dividing the stage of esophageal squamous squamous cancer, but is not limited thereto.
  • the score is calculated from 0 to 4, and if the score is 0, it can be judged as very good, 1 is good, 2 is normal, 3 is bad, and 4 is very bad.
  • the present invention can also provide a method for providing information necessary for predicting the prognosis of esophageal squamous cell carcinoma comprising the following steps.
  • nc886 If the expression level of nc886 is higher than the normal control sample, 0 point is given; if it is lower than the normal sample control, 1 point is given,
  • the expression level of a gene or its protein that decreases due to an increase in expression of nc886 is higher than a normal control sample, or a gene or its protein level that increases by an increase in expression of nc886” 1 point is given if it is lower than the normal control sample;
  • the expression level of a gene or its protein that decreases due to increased expression of nc886” is lower than the normal control sample, or a gene or its protein level that increases by increased expression of nc886” is higher than a normal control sample. If it's high, give it 0,
  • the expression level of a gene or its protein that decreases by increasing the expression of nc886 among genes related to the cell cycle is higher than a normal control sample, or increased by an increase in expression of nc886 among genes related to the cell cycle. If the level of expression of a gene or a protein thereof” is lower than a control sample as expected, 1 point is given; The expression level of a gene or its protein that decreases due to an increase in expression of nc886 among genes related to the cell cycle is lower than a normal control sample, or a gene or its increase that increases by an increase in expression of nc886 among genes related to the cell cycle. If the level of protein expression” is higher than the control sample as expected, give a score of 0,
  • TNM step is 1 or 2, giving 0 points, and if it is 3 or 4, giving 1 point;
  • the score is a score for statistical convenience, and it is clear that it can be calculated by adding weights to items to be measured according to the patient's condition and expression level.
  • the weight is, for example, divided by the number (n)/1 of the number of genes or proteins reduced by the increase in expression of nc886 among the target genes of AKT, scores are added for each gene, and the scores are added to obtain the total weight. Can be added.
  • nc886 + cells may be extended due to the delay in a specific stage of the cell cycle, not due to the death of cells.
  • the cell cycle was analyzed by measuring the DNA content by flow cytometry. Upon nocodazole treatment, cells were synchronized and released from G2/M phase after 6 hours to progress to G1 phase. However, after 12 hours, nc886 ⁇ cells were further advanced into the S phase, whereas in the case of the nc886 + cells, it was confirmed that the progress toward the S phase was delayed (FIGS. 2A and B ).
  • nc886 delays the transition from G1 to S, but does not affect the conversion from G2/M to G1.
  • the G1 extended period of nc886 + cells of nc886 + cells nc886 - indicates that the reason for the slower growth than cells.
  • the present inventors investigated the gene expression pattern to find out why the cells of nc886 + have longer G1 groups than the nc886 - cells.
  • anti-nc886 oligonucleotide that targets and inhibits nc886
  • the same experiment was performed in a non-specific anti-oligo (anti-control) to nc886, which was used as a control (the value of anti-nc886/anti-control is expressed as nc886-KD).
  • nc886 + and original 293T (nc886 - phosphorus) cells the value of nc886 + /nc886 - is denoted by nc886-EXP.
  • Z-scores for 674 pathways were obtained from nc886-EXP and nc886-KD, and a significant negative correlation was observed when plotted as a scatter plot (FIG. 3A).
  • the nc886-EXP and nc886-KD TFT (transcription factors target gene sets; TFT) Z scores also showed a negative correlation (Fig. 3B).
  • nc886/G1-related genes FIG. 4A
  • the genes were analyzed in a population of 108 ESCC patients with nc886 qRT-PCR values and mRNA sequence data available.
  • the majority of nc886/G1-related genes obtained from cellular data (14 of 19) were found to be significantly associated with nc886 in patient data ( Figure 4B).
  • the researchers selected CDKN2A and CDKN2C.
  • nc886 As a result of investigating the expression level in 108 patients with ESCC, CDKN2A and CDKN2C showed changes in the same direction as nc886 (FIG. 4C ). Since SKP2 and CUL1 are known to promote G1-S metastasis by degrading CDK inhibitors, SKP2 and CUL1 were investigated. Expression of these two genes was negatively correlated with nc886 in patient and cell line data ( Figure 4B-D). When the above data were comprehensively judged, nc886 regulates the cell cycle gene to delay G1-S metastasis.
  • nc886 was shown to inhibit PKR and Dicer, we investigated whether delayed G1 in nc886-EXP can be explained by both proteins.
  • PKR is a protein involved in cell proliferation, and its representative downstream phenomenon is activation of NF- ⁇ B. Therefore, NF- ⁇ B was examined in the MSigDB TFT set. PKR induces apoptosis when activated, so it must remain latent in naturally proliferating cells. In this situation, when nc886 was expressed (in nc886-EXP), the additional inhibitory role of nc886 against PKR was hardly observed.
  • PKR is activated by nc886-KD, but the cell cycle phenotype of nc886-EXP could not be explained.
  • MSigDB MIR miRNA target genes
  • AKT1S1 is phosphorylated directly by AKT.
  • AKT phosphorylation was measured in nc886-EXP, which observed the cell phenotype (slow cell proliferation due to delay in G1).
  • Western blot results showed that AKT1 was less phosphorylated in Ser473 than 293T-U6 at 293T-U6:nc886 at 6 and 12 hours after release from the nocodazole suspension (Figure 5B).
  • Figure 5B Western blot results showed that AKT1 was less phosphorylated in Ser473 than 293T-U6 at 293T-U6:nc886 at 6 and 12 hours after release from the nocodazole suspension.
  • Figure 5B Western blot results showed that AKT1 was less phosphorylated in Ser473 than 293T-U6 at 293T-U6:nc886 at 6 and 12 hours after release from the nocodazole suspension
  • nc886-KD 34 increased genes and 19 reduced genes were selected from nc886-KD to apply to the array data for 108 ESCC patients (Table 2 and Table 3).
  • 34 and 19 genes were positively correlated positively with nc886 at statistically significant levels (FIG. 5C ).
  • Concordance of nc886/AKT related genes between nc886-KD data and patient data suggests that nc886 also inhibits the AKT pathway in the tumor formation process in vivo.
  • nc886, AKT and cell cycle genes are a predictor of survival in ESCC patients.
  • the role of nc886 in inhibiting AKT pathway and cell cycle progression was revealed and nc886 related gene characteristics were identified (34 and 19 nc886/AKT-related genes (FIG. 5); 9 and 5 nc886/G1 related genes (FIG. 4B)) .
  • the prognostic usefulness of these genes was tested in 108 ESCC patients.
  • the AKT signature score was generated by the difference in geometric mean between 34 genes up-regulated and 19 genes down-regulated in nc886-KD.
  • the cell cycle signature score was calculated similarly from 9 genes and 5 genes, each negatively correlated with nc886. Cohorts with this score were differentiated according to each median.
  • Stratification into 5 subgroups by prognostic score showed distinct DSS, RFS and OS curves in the 108 ESCC patient population (FIG. 6B ).
  • genes reduced by nc886 are ACLY, BTK, CD14, CDC42, CDKN1A, CDKN1B, DPYSL2, DPYSL3, EIF4E, FOS, FOXO1, FOXO3, FOXO4, GJA1, GRB10, GRB2, HSPB1, JUN, MUN , MAPT, MYC, NFKBIA, PABPC1, PAK1, PALLD, PIK3R1, PPP2R1B, PRKAA1, PRKCA, PRKCZ, SHC1, SREBF1, SRF and YWHAH are any one of the genes selected, and the gene increased by nc886 ATG4B, BCL2L11, CSNK2A1, CTPS, EIF2AK2, FKBP1A, GADD45A, HRAS, MAPK1, MAPKAP1, MTCP1, PCK2, PPP2CB, PPP2R2A, PRKAA2, PTEN, THEM4, YWHAE
  • genes increased by increased expression of nc886 are CDKN2A, RBL1, PPP2R1B, CDKN1A, or CDKN2C
  • genes decreased by increased expression of nc886 are SKP2, CDKN1B, PPP2CB, UBA52, CDK4, RPS27A, SKP2, PPP2CA, PPP2R2A or CUL1.
  • the sample may be at least one selected from the group consisting of formalin-fixed paraffin-embedded (FFPE) samples, fresh tissue, and frozen tissue of tissue containing cancer cells of patients with esophageal squamous cell carcinoma.
  • FFPE formalin-fixed paraffin-embedded
  • PCR polymerase reaction
  • RT-PCR reverse transcriptase reaction
  • Competitive RT-PCR competitive reverse transcriptase reaction
  • Realtime RT-PCR real-time reverse transcriptase reaction
  • RPA RNase protection assay
  • Northern blotting next-generation sequencing (NGS)
  • DNA microarray analysis PCR, reverse transcriptase reaction (RT-PCR), competitive reverse transcriptase reaction (Competitive RT-PCR), real-time reverse transcriptase reaction (Realtime RT-PCR), RNase protection assay ( RPA; RNase protection assay), Northern blotting, next-generation sequencing (NGS), and DNA microarray analysis.
  • the expression level of the protein is Western blot, ELISA (enzyme linked immunosorbent asay), immunostaining, radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immune diffusion method, low It may be measured by one or more methods selected from the group consisting of rocket immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, FACS, and protein chip.
  • prognosis of the present invention means a prediction for a medical ear (eg, long-term viability, disease-free survival, etc.) and includes a positive prognosis (positive prognosis) or a negative prognosis (negative prognosis), wherein the negative prognosis Disease progression or mortality such as recurrence, tumor growth, metastasis, and drug resistance, and a positive prognosis is disease remission, such as no disease, and improvement or stabilization of diseases such as tumor regression It includes.
  • the poor prognosis in esophageal squamous cell carcinoma in the present invention means that the disease-specific survival year, recurrence free survival or overall survival is low (invention) Figure 6B).
  • prediction of the present invention means to guess in advance about the medical ear, and the course of the disease (no disease survival rate, no recurrence survival rate or overall survival period) of a patient diagnosed with esophageal squamous cell carcinoma for the purposes of the present invention. It means guessing in advance.
  • the present invention also provides nc886; And ACLY, BTK, CD14, CDC42, CDKN1A, CDKN1B, DPYSL2, DPYSL3, EIF4E, FOS, FOXO1, FOXO3, FOXO4, GJA1, GRB10, GRB2, HSPB1, JUN, MAP3K5, MAPT, MYC, NFKBA, PANKBD , PIK3R1, PPP2R1B, PRKAA1, PRKCA, PRKCZ, SHC1, SREBF1, SRF, YWHAH, ATG4B, BCL2L11, CSNK2A1, CTPS, EIF2AK2, FKBP1A, GADD45A, HRAS, MAPK1, MAPK2, PAPCPP , THEM4, YWHAE, YWHAG, CDKN2A, CDKN2C, SKP2, UBA52, CDK4, RPS27A, PPP2CA, RBL1 and/or CUL1 genes, or
  • the present invention also provides nc886; And ACLY, BTK, CD14, CDC42, CDKN1A, CDKN1B, DPYSL2, DPYSL3, EIF4E, FOS, FOXO1, FOXO3, FOXO4, GJA1, GRB10, GRB2, HSPB1, JUN, MAP3K5, MAPT, MYC, NFKBA, PANKBD , PIK3R1, PPP2R1B, PRKAA1, PRKCA, PRKCZ, SHC1, SREBF1, SRF, YWHAH, ATG4B, BCL2L11, CSNK2A1, CTPS, EIF2AK2, FKBP1A, GADD45A, HRAS, MAPK1, MAPK2, PAPCPP , THEM4, YWHAE, YWHAG, CDKN2A, CDKN2C, SKP2, UBA52, CDK4, RPS27A, PPP2CA, RBL1 and/or CUL1 genes, or
  • the detectable agent is an antibody, antibody fragment, or aptamer that specifically recognizes the nucleic acid sequence of the gene, its complementary nucleic acid sequence, a fragment of the nucleic acid sequences, or a protein encoded by the nucleic acid sequence. , Avidity (avidity multimer) and / or peptidomimetics (peptidomimetics).
  • the present invention can also provide a biomarker composition for predicting resistance or sensitivity to the anticancer agent palbociclib in esophageal squamous cell carcinoma comprising an agent measuring the mRNA or protein level of the nc886, AKT, CDK4, CDKN2A and CKN2C genes. .
  • Cluster 2 showed the expression of most genes, including CDK4. Increased (FIG. 7A) and low expression of nc886 (FIG. 7B) was confirmed.
  • Palbosiclip is an FDA approved CDK4/6 inhibitor.
  • nc886 associated with CDK4 can predict the response of ESCC cells to Palbociclib.
  • Sensitivity to Palvosilib was investigated in the drug sensitivity genomics ( www.cancerRxgene.org) of the cancer database, the largest public resource providing information on the sensitivity of 1,000 cancer cell lines to over 100 compounds. It was confirmed that nc886 had the lowest IC 50 value suggesting that the silenced ESCC cell line TT (FIG. 7C) was a sensitive drug possessed by Palvosiclip (FIG. 7D).
  • Apoptosis analysis for palbociclib treatment confirmed that TT cells had a higher rate of apoptosis than the nc886 expressing esophageal cell line (FIG. 7E ).
  • nc886 and related genes were confirmed through the above results, it was confirmed that the prognosis of treatment for palbosiclip in patients with esophageal squamous cell carcinoma can be predicted.
  • the present invention can also provide a kit for predicting resistance or sensitivity to the anti-cancer agent Palbosiclip in esophageal squamous cell carcinoma comprising the composition of the above-described composition.
  • the present invention can also provide a method for providing information for predicting resistance or sensitivity to the anticancer agent palbociclib in esophageal squamous cell carcinoma comprising the following steps.
  • nc886, CDKN2A and CKN2C gene mRNA or its protein level is lower than the control
  • AKT and CDK4 gene mRNA or its protein level is higher than the control group
  • esophageal squamous cell carcinoma susceptibility to anticancer agent palbociclib If it is judged that there is, and the mRNA level of the nc886, CDKN2A and CKN2C genes or its protein level is higher than the control group, and the mRNA level of the AKT and CDK4 genes or the protein level thereof is lower than the control group, the anticancer agent in the esophageal squamous cell carcinoma is used as an anticancer agent Determining that there is resistance to.
  • the biological sample is one selected from the group consisting of formalin-fixed paraffin-embedded (FFPE) samples, fresh tissue, and frozen tissue of tissue containing cancer cells of patients with esophageal squamous cell carcinoma. It may be abnormal.
  • the fresh tissue can be tissue, whole blood, serum or plasma.
  • the mRNA levels of step (a) are polymerase reaction (PCR), reverse transcriptase reaction (RT-PCR), competitive reverse transcriptase reaction (Competitive RT-PCR), real-time reverse transcriptase reaction (Realtime RT-PCR), RNase protection assay (RPA), Northern blotting, next-generation sequencing (NGS), and DNA microarray analysis. have.
  • the protein level of step (a) is western blotting, ELISA (enzyme linked immunosorbent assay), radioimmunoassay, radioimmunodiffusion, ouchterlony immunodiffusion, rocket (Rocket) from the group consisting of immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complete fixation assay, flow cytometry (FACS) and protein chip assay It may be measured by one or more methods selected.
  • HEK-293T cells (American Type Culture Collection) were cultured at 5% CO 2 and 37° C. using DMEM medium containing 10% fetal bovine serum and 1% Antibiotic-Antimycotic.
  • the plasmid "pLPCX-U6” was created by inserting the U6 promoter in the pLPCX vector, and the "pCAGGS-GFP” was made by subcloning the green fluorescent protein (GFP) gene into the pCAGGS vector.
  • nc886 expression plasmids (“pLPCX-U6-pre-886” and “pCAGGS-GFP/nc886”) were inserted into the vectors (“pLPCX-U6” and “pCAGGS-GFP”) (length as simulated in FIG. 1A) (101nt-649nt).
  • Clones isolated by standard plasmid protocol were transformed into HEK-293T cells with LipofectamineTM 2000 reagent and nc886 + or nc886 ⁇ cell lines were established.
  • Antibodies to phosphorylation-AKT (Ser 473), AKT and GAPDH were purchased from Cell Signaling Technology (Beverly, MA).
  • Example 2 Measurement of cell proliferation, cell synchronization and cell cycle analysis
  • RNA from 293T-derived nc886 + or control cells was isolated using Trizol reagent (Life Technologies) according to the manufacturer's instructions. DNA was synthesized with amfiRivert kit (GenDEPOT). nc886 was amplified by AccuPower Taq PCR PreMix (BIONEER) and the PCR product was visualized on an agarose gel. MRNAs for CDKN2A, CDKN2C, CUL1 and SKP2 were quantified with qRT-PCR using AccuPower GreenStarTM qPCR MasterMix (BIONEER) and ExicyclerTM 96 Real-Time Quantitative Thermal Block (BIONEER). The primers used for this are shown in Table 1 below.
  • PET-CT Positron emission tomography-CT
  • esophageal dystrophy were performed annually or more often, if necessary, depending on clinical history and clinical findings. All human specimens were collected with informed patient consent and the study protocol was approved by the Institutional Ethics Committee. After obtaining frozen tissue, total RNA was extracted using the mirVanaTM miRNA Isolation Kit (Ambion, Inc., Austin, TX) according to the manufacturer's instructions.
  • RNA of 293T-U6 and 293T-U6:nc886 cells was treated with Affymetrix Human Genome U133 Array (Affymetrix, Santa Clara, CA).
  • Affymetrix Human Genome U133 Array Affymetrix, Santa Clara, CA.
  • 750 ng of total RNA was labeled with the Total Prep RNA Amplification Kit (Illumina) and hybridized.
  • the micro-array data was normalized through quantile normalization, and the normalized values were algebraically converted to base 2 scale with R-script.
  • the microarray data is stored in the Gene Expression Omnibus database of the National Center for Biotechnology Information (GSE55856 for ESCC samples and GSE51732 for Het-1A).
  • RPPA data was performed at the Department of System Biology at the MD Anderson Cancer Center.
  • RPPA lysis buffer 1% Triton X-100, 50mM HEPES (pH 7.4), 150mM NaCl, 1.5mM MgCl2, 1mM EGTA, 100mM NaF, 10mM Na pyrophosphate, 1mM Na3VO4, 10% glycerol, 1mM phenylmethylsulfonyl fluoride and 10 ⁇ g/ml aprotinin
  • Cell lysates were initially adjusted to 1 ⁇ g/ ⁇ l and diluted 5 fold in lysis buffer to continuously print on nitrocellulose coated slides (Grace Bio-Labs, Bend, OR).
  • Palbosiclip (PD0332991) HCl (catalog no. S116) was purchased from Selleckchem. 10 6 cells from each cancer cell line were plated in 6-well plates and cultured overnight. Cells were treated with 5 ⁇ M of Palboshi Clip and then incubated for 24 hours. Cell suicide analysis was performed by flow cytometry using nnexin V-FITC and 7-AAD (BioLegend. Catalog No. 640922).
  • DSS Disease specific surviva
  • RFS recurrence-free survival
  • OS overall survival
  • Univariable Cox regression analysis was used to determine if the variable was related to survival.
  • c886 expression, gene marker and TNM (tumor-node-metastasis) stage were used as variables.
  • C statistics from the R language and software environment http://www.r-project.org) were used to calculate the coincidence index between variables and survival. When p ⁇ 0.05, it was judged that there was statistical significance, and all tests were conducted in two-tailed. All statistical analyzes were performed with SPSS 24.0 (released at IBM Corp. 2016, IBM SPSS Statistics for Windows version 24.0, Armonk, NY).
  • nc886 was a tumor suppressor in ESCC patient data.
  • Het-1A a non-malignant esophageal cell line expressing nc886, was subjected to nc886 knockdown (KD) to obtain Het-1A with nc886 knockdown.
  • KD nc886 knockdown
  • nc886 Het-1A would be more tumorigenic (eg increased cell growth).
  • nc886 knockdown-Het-1A expressed several tumor genes.
  • nc886 KD results in the activation of PKR and the resulting apoptosis, which is consistent with previous studies that nc886 acted as an inhibitor of the pro-apoptotic protein PKR.
  • PKR-mediated apoptosis surpasses all of the other effects of nc886-KD (tumor promoting gene expression) on Het-1A cells, making all further experiments to observe cell phenotype impossible. Therefore, when nc886 was deficient, it was judged that it was not easy to observe the phenotype of the cell, and when nc886 was expressed (gain-of function), it was switched to an approach for observing cells.
  • nc886 is epigenetally silent in ESCC cells (nc886 - cells), and by expressing nc886 from several ESCC cell lines, an attempt was made to create an ESCC cell line with the same genetic background as the original cell line except for nc886 expression. .
  • nc886 clone could not be isolated. It was assumed that these ESCC cells should be in the nc886 - phosphorus state, so that cell proliferation was possible, and thus did not proliferate when artificially produced nc886+ ESCC. Therefore, the human embryonic kidney cell line HEK-293T transformed with the SV40 T antigen (hereinafter referred to as "293T") was used. The use of 293T was chosen as an alternative, but it is a reasonable alternative because the effect of nc886 on gene expression is similar between 293T and Het-1A cells. Two versions of the nc886 293T cell line and corresponding vector control lines (see FIG.
  • GFP + / GFP - cells in 293T-GFP / nc886 or 293T-GFP cells the original 293T cells that do not express GFP (GFP) - expressing GFP to monitor the rate of Were traced (Figure 1D).
  • GFP cells were depleted as the co-culture continued, and importantly, the depletion was 293T-GFP/nc886 more severe than 293T-GFP (FIGS. 1E-F). When the above data were comprehensively judged, it was confirmed that the cells of nc886 proliferated slowly.
  • nc886 + cells have a longer G1 duration than nc886 - cells
  • nc886 + cells have a longer G1 duration than nc886 - cells. It was hypothesized that the delayed growth of nc886 + cells was due to delays at certain stages of the cell cycle.
  • cells growing asynchronously were treated with microtubule inhibitor nocodazole and then profiled with a cell cycle using flow cytometry (FIG. 2A ).
  • flow cytometry flow cytometry
  • cells growing asynchronously were treated with microtubule inhibitor nocodazole and then profiled with a cell cycle using flow cytometry (FIG. 2A ). Upon nocodazole treatment, cells were synchronized at the G2/M step as identified by a single peak at a DNA content of 2n. After 6 hours of nocodazole removal, another peak appeared at the 1n position, and the above results indicate that the cells were released from G2/M and entered the G1 phase.
  • nc886 + and nc886 ⁇ cells showed almost the same pattern at this point. However, after 12 hours, it was confirmed that nc886 ⁇ cells further progressed to S (S phage), whereas progression to the S phase was delayed in the case of nc886 + cells (FIGS. 2A and B ).
  • S phage S phage
  • progression to the S phase was delayed in the case of nc886 + cells
  • the above data indicate that nc886 reverses the transition from G1 to S, but does not affect the conversion from G2/M to G1.
  • the extension of the G1 period nc886 + cell is a cell of nc886 + nc886 - indicates whether more slowly than cell proliferation.
  • nc886 has a gene regulation function
  • the gene expression pattern was examined to find out why the cells of nc886 + have a longer G1 phase than nc886 - cells.
  • Microarrays were performed on the pair of cell lines used in Figures 1 and 2 ("nc886-EXP" compared to 293T-U6, relative values of 293T-U6:nc886). A significant proportion of the genes altered in nc886-EXP would be secondary outcomes. This is because these cells have been maintained for several months until the microarray experiment. Therefore, nc886-EXP data was supplemented with nc886 KD data (“anti-nc886 value compared to control).
  • nc886-KD was constructed by transiently transfecting Het-1A cells with anti-nc886 (oligonucleotides targeting and inhibiting nc886) for a few days. Therefore, the nc886-KD data showed that The direct results are better represented: Array data was analyzed for the Molecular Signature Database (MSigDB: http://software.broadinstitute.org/gsea/msigdb) as array data.MSigDB has several sequences based on sequence motifs, pathways, etc. There is a gene collection, for example, a TFT is a collection of target genes for transcription factors (TF), there are 615 sets of TFTs, each set has dozens to hundreds of binding sites for that TF in the promoter region.
  • MSigDB Molecular Signature Database
  • Another example is a set of 674 Reactome sets defined by the Reactome pathway database
  • the overall enrichment or depletion of the set is calculated from the array values of the genes in the set.
  • 674 Z- scores were obtained from nc886-EXP and nc886-KD, and a significant negative correlation was observed compared to the scatterplot (FIG.
  • the TFT Z scores of nc886-EXP and nc886-KD also showed a negative correlation (Fig.
  • nc886 was similar to the cellular pathway of the esophageal cell line Het-1A in the gene expression and cell pathway of 293T cells. It suggests that it has no effect, suggesting that 293T is suitable for investigating the role of the tumor suppressor factor of nc886 in ESCC
  • Individual genes were examined to see the pathway or TF most affected by nc886. 9 paths in EXP (Z-score Score was cut off >3) was significantly activated (blue bar in FIG. 3). Note that most of the 9 pathways (8 of 9) are somehow related to the cell cycle, and 3 are directly related to the G1/S phase (FIG. 3C, shown in red brackets).
  • CDKN2A aka, p16INK4a or p14ARF
  • CDKN2C CDKN2C for further experiments. This is because it has been reported that inhibiting CDK4/CDK6 restricts cells in G1 and is activated by E2F.
  • CDKN2A and CDKN2C showed a positive response with nc886 (FIG. 4C ).
  • CDKN2A and CDKN2C in 293T-U6:nc886 cells increased in line with the long-term persistence of G1 (Figure 2A-B) and enrichment of E2F target genes (Figure 3D) compared to 293T-U6 cells.
  • SKP2 and CUL1 are known to promote G1-S metastasis by degrading CDK inhibitors, so SKP2 and CUL1 were investigated.
  • These two genes were negatively correlated with nc886 in patient and cell line data ( Figure 4B-D). When the above data were comprehensively judged, nc886 regulates the cell cycle gene to delay G1-S metastasis.
  • nc886 was shown to inhibit PKR and Dicer, we investigated whether delayed G1 in nc886-EXP could be explained by these two proteins.
  • PKR is a protein involved in cell proliferation and its representative downstream phenomenon is activation of NF- ⁇ B. Therefore, NF- ⁇ B was examined in the MSigDB TFT set. As described above, PKR induces cell death when activated, so it must remain latent in naturally proliferating cells. In this situation, the inhibitory role of nc886 on PKR has little effect. Although activated by nc886-KD, PKR was unable to explain the cell cycle phenotype of nc886-EXP.
  • the major enzyme of miRNA biogenesis, Dicer was studied to investigate the set of miRNA target gene, MSigDB MIR. No inhibitory effect of nc886 on miRNA pathway was observed in nc886-EXP.
  • nc886 inhibits the AKT pathway.
  • RPPA proteome repertoire was measured using a high-efficiency platform called RPPA.
  • cell lysates were arranged on nitrocellulose coated slides containing 172 antibodies, and the corresponding protein was comprehensively measured.
  • the antibody contained a protein and its phosphorylated form in a well-known route.
  • RPPA was run on nc886-KD. This is because, as described above, when identifying the direct effect of nc886, short-term KD cells are more advantageous than nc886-EXP.
  • Expression values of 72 proteins were obtained and 23 were found to change at statistically significant levels (FIG. 5A ). When the 23 proteins were examined, it was confirmed that there was a change in the protein in the AKT pathway.
  • the AKT protein consists of three isoforms with strong homology (AKT1, AKT2 and AKT3), and their phosphorylation is active.
  • phosphorylation of AKT1 in Thr308 and Ser473 increased, and total AKT1 remained relatively unchanged (FIG. 5A ).
  • nc886-KD increased phosphorylation of substrate 1 (AKT1S1, a.k.a., PRAS40) of AKT1 and Ribosomal Protein S6 (RPS6).
  • AKT1S1 is phosphorylated directly by AKT.
  • RPS6 is phosphorylated by AKT-promoted Ribosomal Protein S6 Kinase B1 (RPS6KB1, a.k.a., S6K).
  • RPS6KB1 AKT-promoted Ribosomal Protein S6 Kinase B1
  • AKT phosphorylation was measured in nc886-EXP, which observed the cell phenotype (slow cell proliferation due to delay in G1).
  • Western blot results showed that AKT1 was less phosphorylated in Ser473 than 293T-U6 at 293T-U6:nc886 at 6 and 12 hours after release from the nocodazole suspension (FIG. 5B ).
  • the data demonstrated the suppression of AKT by nc886.
  • AKT activation leads to changes in gene expression. Therefore, the effect of nc886 on AKT was further evaluated in gene expression data. Collection of recent review articles and public databases including Reactome and Biocarta gene sets (http://software.broadinstitute.org/gsea/msigdb/) and RGD (Rat Genome Database; https://rgd.mcw.edu/) A list of 184 AKT downstream genes was selected. Some of these genes are down-regulated while others are down-regulated when AKT is activated. To apply to the array data for 108 ESCC patients, 34 increased genes (Table 2) and 19 reduced genes were selected from nc886-KD among 184 genes (Table 3).
  • Example 13 Association between nc886, AKT and cell cycle genes is a predictor of survival in ESCC patients.
  • nc886, AKT and cell cycle genes are a predictor of survival in ESCC patients.
  • the role of nc886 in inhibiting AKT pathway and cell cycle progression was revealed and nc886 related gene characteristics were identified (34 and 19 nc886/AKT-related genes (FIG. 5); 9 and 5 nc886/G1 related genes (FIG. 4B)) .
  • the prognostic usefulness of these genes was tested in 108 ESCC patients.
  • the AKT signature score was generated by the difference in geometric mean between 34 genes up-regulated and 19 genes down-regulated in nc886-KD.
  • the cell cycle signature score was calculated similarly from 9 genes and 5 genes, each negatively correlated with nc886.
  • TNM staging and nc886 expression were independent prognostic factors for RFS. According to C-statistics, the combination of the four factors (expression level of nc886, AKT signature score, cell cycle signature score and TNM stage) was the strongest combination that could predict disease recurrence and patient survival (FIG. 6A ).
  • Stratification into 5 subgroups by prognostic score showed distinct DSS, RFS and OS curves in the 108 ESCC patient population (FIG. 6B ). In all three curves, the higher the prognosis score is, the shorter the survival time is. Patients with a score of 4 (TNM Stage III and IV, low nc886, high AKT signature score and high cell cycle score) had the worst survival, but those with a score of 0 had the best survival. AKT downstream genes and cell cycle genes better predicted patient survival when combined with nc886 and TNM staging. To demonstrate how nc886 acts as a tumor suppressor in ESCC, the inhibitory role of nc886 in cell proliferation was demonstrated by identifying AKT and cell cycle genes as downstream events (FIG. 6C ).
  • Example 14 Therapeutic application to ESCC with undesirable prognosis.
  • nc886 As an inverse approach to demonstrating the association of nc886 with the AKT target gene and cell cycle gene, unsupervised clustering of 108 patients with the gene was performed to identify two distinct clusters named "Cluster1" and "Cluster2" (Fig. 7A). Cluster2 enriched most of the genes, including low expression of CDK4 ( Figure 7A) and nc886 ( Figure 7B). Some cancer drugs target cell cycle genes.
  • the FDA-approved small molecule CDK4/6 inhibitor, Palbociclib has been extensively investigated in preclinical studies and clinical trials of a series of human malignancies, including EC. The investigation of nc886, AKT and cell cycle further investigated whether treatment decisions were further improved based on the gene expression profile of the tumor.
  • nc886 and related genes were confirmed through the above results, it was confirmed that the prognosis of treatment for palbosiclip in patients with esophageal squamous cell carcinoma can be predicted. It was confirmed that the nc886, CDKN2A and CKN2C gene levels were lower than the control group, and the AKT and CDK4 gene levels were higher than the control group.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un méthode pour établir le pronostic d'un carcinome épidermoïde oesophagien.
PCT/KR2019/017213 2018-12-06 2019-12-06 Méthode pour établir le pronostic d'un carcinome épidermoïde oesophagien WO2020117002A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180156444 2018-12-06
KR10-2018-0156444 2018-12-06

Publications (1)

Publication Number Publication Date
WO2020117002A1 true WO2020117002A1 (fr) 2020-06-11

Family

ID=70973881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/017213 WO2020117002A1 (fr) 2018-12-06 2019-12-06 Méthode pour établir le pronostic d'un carcinome épidermoïde oesophagien

Country Status (2)

Country Link
KR (3) KR102359423B1 (fr)
WO (1) WO2020117002A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113777311A (zh) * 2021-09-16 2021-12-10 郑州大学 一种用于食管鳞癌辅助诊断的elisa试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096768A1 (en) * 2000-03-31 2008-04-24 University Of Southern California Epigenetic sequences for esophageal adenocarcinoma
CN103149369A (zh) * 2013-03-20 2013-06-12 江苏元化生命科技有限公司 一种检测食管鳞癌标志物的蛋白质芯片及其试剂盒
KR20180015587A (ko) * 2016-08-02 2018-02-13 국립암센터 암 예후 예측용 바이오마커

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI429910B (zh) * 2011-10-17 2014-03-11 Univ Kaohsiung Medical 預測食道癌存活及癒後狀態之方法及其套組及微陣列晶片

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080096768A1 (en) * 2000-03-31 2008-04-24 University Of Southern California Epigenetic sequences for esophageal adenocarcinoma
CN103149369A (zh) * 2013-03-20 2013-06-12 江苏元化生命科技有限公司 一种检测食管鳞癌标志物的蛋白质芯片及其试剂盒
KR20180015587A (ko) * 2016-08-02 2018-02-13 국립암센터 암 예후 예측용 바이오마커

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEE, H.-S.: "Epigenetic silencing of the non-coding RNA nc886 provokes on cogenes during human esophageal tumorigenesis", ONCOTARGET, vol. 5, no. 11, 15 June 2014 (2014-06-15), pages 3472 - 3481, XP055716831 *
LEE, Y. S.: "A novel type of non-coding RNA, nc886, implicated in tumor sensing and suppression", GENOMICS & INFORMATICS, vol. 13, no. 26, 1 January 2015 (2015-01-01), pages 26 - 30, XP055461430 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113777311A (zh) * 2021-09-16 2021-12-10 郑州大学 一种用于食管鳞癌辅助诊断的elisa试剂盒
CN113777311B (zh) * 2021-09-16 2023-08-01 郑州大学 一种用于食管鳞癌辅助诊断的elisa试剂盒

Also Published As

Publication number Publication date
KR102359423B1 (ko) 2022-02-09
KR20210117238A (ko) 2021-09-28
KR20200069258A (ko) 2020-06-16
KR102348837B1 (ko) 2022-01-11
KR102417314B1 (ko) 2022-07-07
KR20210116403A (ko) 2021-09-27

Similar Documents

Publication Publication Date Title
Wang et al. miR-206 inhibits cell migration through direct targeting of the actin-binding protein Coronin 1C in triple-negative breast cancer
Pan et al. Hsa_circ_0006948 enhances cancer progression and epithelial-mesenchymal transition through the miR-490-3p/HMGA2 axis in esophageal squamous cell carcinoma
Bois et al. FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts
Marcel et al. p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer
Yoshimatsu et al. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers
Zhang et al. Upregulation of miR-572 transcriptionally suppresses SOCS1 and p21 and contributes to human ovarian cancer progression
Viré et al. The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31
Zo et al. MiR‐124‐3p suppresses bladder cancer by targeting DNA methyltransferase 3B
Inaguma et al. GLI1 interferes with the DNA mismatch repair system in pancreatic cancer through BHLHE41-mediated suppression of MLH1
Liu et al. Isocitrate dehydrogenase 1–snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability
Su et al. LncRNA MIR22HG abrogation inhibits proliferation and induces apoptosis in esophageal adenocarcinoma cells via activation of the STAT3/c-Myc/FAK signaling
Hu et al. miR‐636 represses cell survival by targeting CDK6/Bcl‐2 in cervical cancer
Fang et al. The CREB coactivator CRTC2 is a lymphoma tumor suppressor that preserves genome integrity through transcription of DNA mismatch repair genes
Zhao et al. miR-1323 promotes cell migration in lung adenocarcinoma by targeting Cbl-b and is an early prognostic biomarker
Zhang et al. miR-21-5p promotes cell proliferation by targeting BCL11B in Thp-1 cells
Von Roemeling et al. Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration
Wang et al. LHPP suppresses tumorigenesis of intrahepatic cholangiocarcinoma by inhibiting the TGFβ/smad signaling pathway
WO2018026190A1 (fr) Biomarqueur pour prédire un pronostic d'un cancer
US8501404B2 (en) Gnaq mutations in melanoma
Bai et al. Linc00963 promote cell proliferation and tumor growth in castration-resistant prostate cancer by modulating miR-655/TRIM24 axis
WO2020117002A1 (fr) Méthode pour établir le pronostic d'un carcinome épidermoïde oesophagien
Pei et al. CircFOXM1 acts as a ceRNA to upregulate SMAD2 and promote the progression of nasopharyngeal carcinoma
Huang et al. MCTS1 promotes invasion and metastasis of oral cancer by modifying the EMT process
WO2018004240A1 (fr) Utilisation de nupr1 dans le diagnostic et le traitement de la tumeur au cerveau
WO2017164568A1 (fr) Procédé de prédiction du taux de survie et du pronostic de patient présentant un cancer de l'œsophage en mesurant le niveau d'expression de protéine de la sous-unité v-atpase v1e1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19893850

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19893850

Country of ref document: EP

Kind code of ref document: A1